2 recruiting, 1 completed. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow MK-0616: new trials by email Literature Review of MK-0616 trials Research Report on MK-0616
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004) MK-7262, Enlicitide, Placebo for MK-7262 - Lipoprotein(a) | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 750 | 2026-06-30 | 2026-11-12 |
| A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) Enlicitide Decanoate, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 153 | 2025-08-21 | 2026-11-12 |
| A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008) Enclitide Chloride, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 381 | 2022-03-10 | 2024-12-09 |
Hypercholesterolemia (1) · Hyperlipoproteinemia Type II (1)
Germany (3) · Japan (3) · United States (3) · Colombia (2) · Mexico (2) · Netherlands (2) · Norway (2) · Spain (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · China (1)
2025 (1)